Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS). (August 2016)

• Record Type: Journal Article
• Authors: Lamichhane, D; Weinstein, A
• Is Part Of: Lupus. Volume 25:Number 9(2016)
• Page Start: 1050
• Page End: 1053
• Publication Date: 2016-08
• Subjects: Systemic lupus erythematosus (SLE) -- cell-bound complement activation products (CB-CAPS) -- neuromyelitis optica (NMO) -- complement; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203316635287
• Languages: English
• ISSNs: 0961-2033

Abstract

Complement activation is a key feature of systemic lupus erythematosus (SLE). Detection of cell-bound complement activation products (CB-CAPS) occurs more frequently than serum hypocomplementemia in definite lupus. We describe a patient with normocomplementemic probable SLE who did not fulfill ACR classification criteria for lupus, but the diagnosis was supported by the presence of CB-CAPS.